Fresh analysis suggests that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass far faster than those who halt conventional diet and exercise programs.
Published data in a prominent medical journal demonstrates that while obese individuals can lose about a fifth of their body weight while on the medication, the weight comes back at an average rate of nearly a kilo each month once they quit.
"People buying such medications should be aware of the potential of rapid weight regain when the medication concludes," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment mass within about one and a half years.
Weighing Treatments
The research, which examined dozens of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
The team point out that people who lose weight through diet and exercise generally experience a slower weight regain—around 0.1 kg a month—post-intervention.
Understanding the Quick Rebound
Nutrition scientists propose the mechanism of the jabs explains the accelerated rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels far above than normal may cause the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement leads to hunger is unsuppressed, making overeating a significant risk."
An Ongoing Condition?
Health authorities advise the jabs for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Professionals contend that, given the significant potential of weight regain, the treatment is often long-term.
This opinion is supported by pharmaceutical companies, who say that the findings "highlight the persistent character of excess weight," similar to managing conditions like hypertension.
Patient Accounts
Individuals who have discontinued the medication report a intense return of appetite.
"It felt as if something flipping and you're instantly extremely hungry," recalled an individual.
This challenge is exacerbated if individuals have not developed permanent dietary or behavioural modifications during therapy.
Significant Adoption
Figures indicate that a significant number of people in the UK have used these injections in the last 12 months, with demand remaining high.
- Adoption is greater among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, experts caution that while the jabs are effective agents for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on integrated lifestyle support.
